This site is intended for healthcare professionals
News

Rafael Pharmaceuticals provides update on pivotal phase III clinical trial in patients with metastatic adenocarcinoma of the pancreas.

Read time: 1 mins
Published:2nd Nov 2021
Rafael Pharmaceuticals, Inc. announced that the AVENGER 500 Phase iII clinical trial evaluating the efficacy and safety of CPI-613 (devimistat) in combination with modified FOLFIRINOX (mFFX) as a first-line therapy in patients with metastatic adenocarcinoma of the pancreas did not meet its primary endpoint of overall survival.

In this multi-national Phase III randomized clinical trial, 528 patients with metastatic adenocarcinoma of the pancreas who had no prior therapy were randomized to receive either devimistat in combination with modified FOLFIRINOX (mFFX) or FOLFIRINOX, a current standard of care chemotherapy regimen. Devimistat given with mFFX did not significantly improve overall survival (HR=0.95, p=0.66). The median overall survival in the devimistat and mFFX arm was 11.1 months, compared to 11.7 months in the FOLFIRINOX arm.

Condition: Pancreatic Cancer
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.